LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 1.60 -0.30 (-15.79%) As of 07/24/2026 10:07 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Proteome Sciences Stock (LON:PRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Proteome Sciences alerts:Sign Up Key Stats Today's Range 1.60▼ 250-Day Range 1.30▼ 2.1752-Week Range 1.20▼ 4.40Volume41,626 shsAverage Volume401,084 shsMarket Capitalization£5.61 millionP/E RatioN/ADividend Yield6.17%Price TargetN/AConsensus RatingN/A Company Overview Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom. Read More Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRM Stock News HeadlinesProteome Sciences secures further clinical contractJune 22, 2026 | lse.co.ukProteome Sciences Secures New Chemoproteomics Contract Ahead of Planned 2026 Clinical Programme (PRM)June 22, 2026 | uk.finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 26 at 1:00 AM | Porter & Company (Ad)Proteome Sciences Wins New Chemoproteomics Contract Ahead of 2026 Trial ProgrammeJune 22, 2026 | tipranks.comProteome Sciences Wins Full Shareholder Backing at AGMMay 14, 2026 | tipranks.comProteome Sciences shares rise as chair hails rebound in businessMay 16, 2025 | lse.co.ukProteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)April 12, 2025 | finance.yahoo.comProteome Sciences Secures £1 Million Loan to Boost Capacity Amid Market GrowthDecember 23, 2024 | tipranks.comSee More Headlines PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 2.50 on January 1st, 2026. Since then, PRM shares have decreased by 36.0% and is now trading at GBX 1.60. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) announced its quarterly earnings data on Wednesday, April, 15th. The company reported ($1.04) earnings per share for the quarter. The company had revenue of $3.76 million for the quarter. Proteome Sciences had a positive trailing twelve-month return on equity of 33.80% and a negative net margin of 81.50%. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings4/15/2026Today7/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryChemicals Current SymbolLON:PRM CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.08 million Net Margins-81.50% Pretax MarginN/A Return on Equity33.80% Return on Assets-19.25% Debt Debt-to-Equity Ratio-165.46 Current Ratio0.13 Quick Ratio0.37 Sales & Book Value Annual Sales£3.76 million Price / Sales1.49 Cash FlowGBX 0.43 per share Price / Cash Flow3.73 Book ValueGBX (1.78) per share Price / Book-0.90Miscellaneous Outstanding Shares350,725,000Free FloatN/AMarket Cap£5.61 million OptionableNot Optionable Beta0.15 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:PRM) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...Golden Portfolio | SponsoredThe invention Elon called the greatest in historyJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
